Trials / Active Not Recruiting
Active Not RecruitingNCT02673333
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2019-01-11
- Completion
- 2027-02-01
- First posted
- 2016-02-03
- Last updated
- 2026-04-06
- Results posted
- 2020-01-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02673333. Inclusion in this directory is not an endorsement.